The sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, has identified a potential new therapeutic target for Ewing sarcoma, the second most frequent bone cancer in children and adolescents, and a tumour known by its aggressiveness and tendency to metastasise.
![](https://www.crbf.org.au/wp-content/uploads/2018/04/Screen-Shot-2020-06-16-at-6.55.51-pm-1.png)